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ABSTRACT
Introduction: The study details the experiences
of Medicare, Medicaid and privately insured
patients with diabetes in the United States by
focusing on how these distinct populations
perceive their disease and manage their
treatment.
Methods: A national survey was fielded among
a representative sample of 2,307 US adult
diagnosed diabetes patients to investigate
demographic, lifestyle, treatment, access to
information, and socioeconomic status. This
was achieved using a combination of telephone-
based interviews and internet-based
questionnaires administered via
KnowledgePanel, the only large-scale online
panel based on a representative random sample
of the US population.
Results: Patients with Medicaid-based
insurance face significant differences in
diagnosis, treatment and intensity of their
diabetes as compared to their Medicare and
privately insured counterparts. Medicaid
patients develop diabetes at an earlier age with
an increased level of severity, and face
significant socioeconomic concerns. Medicaid
patients also have different health information
seeking preferences than their counterparts,
impacted by technology use patterns and
education preferences. All groups report
challenges in paying for their diabetes care,
though cost-sharing requirements are relatively
low.
Conclusions: Significant variation in
experience between Medicaid, Medicare, and
privately insured patients can inform disease
management and patient engagement
strategies. Payers, clinicians and public health
agencies can leverage these findings to design
initiatives more effectively and understand how
intergroup variability impacts program uptake
and disease outcomes.
Electronic supplementary material The online
version of this article (doi:10.1007/s13300-015-0109-z)
contains supplementary material, which is available to
authorized users.
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INTRODUCTION
Diabetes mellitus is currently the seventh
leading cause of mortality in the United States,
and represents a significant economic and
public health burden [1]. Presently, there are
21 million Americans diagnosed with diabetes,
with approximately 8.1 million still
undiagnosed and over 79 million with at-risk
blood glucose levels [1, 2]. Diabetes is associated
with a number of severe comorbidities,
including visual impairment, lower extremity
conditions/amputation, neuropathy, renal
disease and cardiovascular disease [2].
With this rapidly growing patient base and
high rates of severe comorbidities, diabetes is a
major clinical and economic concern for payers
and employers. In April 2013, the American
Diabetes Association (ADA) released a
comprehensive examination of costs in the US
directly attributable to diabetes. In this report,
the estimated annual cost of diabetes in the US is
$245 billion, with $176 billion in direct medical
costs and $69 billion in reduced productivity [3].
When examined over a 5-year period, direct
medical costs of diabetes care have increased
more than 30% over the rate of inflation, a
number directly attributable to increased
prevalence in the U.S. [3]. Previous studies have
shown that this expenditure is attributable to
uncontrolled diabetes, especially within the
Medicare and Medicaid populations [3–5].
The United States Centers for Disease
Control and Prevention (CDC) and the ADA
have outlined preventative care measures for
diabetes patients, including routine blood
pressure screening, glycated hemoglobin
(HbA1c) testing at least two times per year,
blood and urine testing for nephropathy
assessment, blood lipid tests, thorough foot
exams, eye examinations for retinopathy at
least once a year, and smoking/tobacco
cessation advice and treatment [6, 7]. The ADA
also recommends regular diabetes self-
management education (DSME) by accredited
facilities held to strict patient curriculum
standards [8]. Adherence to these guidelines,
particularly those concerning HbA1c and blood
lipid tests, has been previously proven to
contribute directly to improved long-term
clinical outcomes in people with diabetes [9].
Despite these efforts, a vast discrepancy in
adherence to these standards exists across
different insurance types, races/ethnicities, and
socioeconomic statuses (SES), resulting in many
Americans with diabetes not receiving the
appropriate care or education [10, 11]. For
example, there is variability in access to health
care providers (HCP), DSME, prescription
coverage; as well as in the levels of adherence
to medication across different racial groups,
with black and Hispanic patients having lowest
access and levels of adherence [8, 12, 13]. The
discrepancies in diabetes care provision across
socio-demographic groups are exacerbated by a
higher disease prevalence among black and
Hispanic patients than in non-Hispanic white
patients: 13.2% of non-Hispanic black patients
and 11.9% of Hispanic patients have diabetes,
both rates significantly higher than non-
Hispanic white patients at 7.1% [2]. However,
racial disparities alone do not explain
differential outcomes for people with diabetes.
Recent studies have found that access to
insurance coverage is the most powerful
determinant of proper care for people with
diabetes [11, 14]. Insured patients have greater
access to clinicians, treatment and education
generally, but little is known about the different
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attitudes and behaviors of people with diabetes
by payer subgroup. Specifically, do Medicaid,
Medicare, and privately insured people with
diabetes differ significantly in their journey,
access to information, use of internet
education, overall patient experience of their
disease, or cost burden related to their disease?
As adherence and poor outcomes remains a
critical issue for people with diabetes across all
payer subgroups, more needs to be understood
in how these populations are both consistent
and differ.
It has been previously demonstrated that
33–69% of medication-based hospitalizations
for people with diabetes are related to non-
adherence, resulting in an annual cost of
approximately $100 billion [15] with
significant burden among publically insured
Medicaid and Medicare patients. In 2014, the
Affordable Care Act (ACA) was implemented,
extending Medicaid coverage to an estimated
13.6 million currently uninsured, non-elderly
adults. While this population displays better
overall health, including better self-reported
health status, lower overall body mass index
(BMI) and lower rates of diabetes and depression
than current Medicaid recipients, they also are
characterized by higher rates of
smoking/tobacco use and heavy alcohol
consumption [16]. Understanding how these
recently insured patients act in relation to other
insured people with diabetes will help inform
diabetes management activities targeting
Medicaid patients. Additionally, looking more
closely at the privately insured people with
diabetes, where outcomes and adherence levels
are better as compared to Medicaid and
Medicare patients provides an opportunity to
bring best practices to other groups.
For example, many private insurers have
introduced specific programs targeting
treatment adherence and self-management for
people with diabetes. Digital health
management solutions, utilizing both internet-
connected computer and smartphone-based
platforms are also being deployed to improve
patient outcomes within certain payers’
populations [17–19]. Studies have shown a
direct correlation between the use of
information technology systems for diabetes
self-management and improved metrics of
overall health [20]. However, the applications
available today have only been shown effective
as supplementary support to traditional DSME
and do not yet provide a comprehensive set of
tools for self-management [21]. Furthermore,
these solutions often require access to the
internet and smartphones, a premise which
may work fine for most privately insured
patients but because elderly patients and those
with lower SES have lower utilization rates,
could cause access hurdles or lead to diminished
use [22].
Putting these factors together, questions
remain as to how differently insured
populations compare to each other in terms of
disease experience and types of disease
management approaches that are likely to
succeed within each group. This study
examines Medicaid, Medicare and Privately
insured populations of diabetes patients to
elucidate the key differences between them
and how this information could inform future
program and policy making.
METHODS
Patient Selection
The sample for the telephone component was
generated via random digit dialing screening of
c. 51,000 US households between February and
May 2013. Households were qualified via the
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question, ‘‘Have you or has any other member
of your household been told by a doctor or
health professional that you or they have
diabetes?’’ Sample for the Internet component
came from GfK’s KnowledgePanel, the only
large-scale, national probability based panel
that provides the highest level of accuracy and
sample representativeness available in online
research for measurement of public opinion,
attitudes, and behaviors. Respondents were
selected via address-based sampling derived
from the US Postal Service’s Delivery Sequence
File. Randomly selected addresses were invited
to participate based on a series of bilingual
mailings (English and Spanish). Panelists were
pre-identified as having been diagnosed with
diabetes, which was confirmed at the time of
interview. Respondents from non-internet
households were provided Windows-based
laptops. Internet interviews were conducted in
both English and Spanish.
Data Collection and Analysis
Respondents completed a 50-min interview
covering demographics, diabetes treatment,
blood glucose testing, diabetes self-
management behaviors and attitudes, and
diabetes information sources. The
questionnaire was scripted in Base Professional
(SPSS Data Collection Version 6.0, IPS Armonk
NY, USA). Data were collected via IBM SPSS Data
Collection (Version 6.0, IPS Armonk NY, USA),
an online platform. Telephone interviews were
entered during survey administration by the
interviewers, while internet interviews were
entered by independently by respondents.
Data cross tabulations were produced using
Quantum (Version 5.8.1, IBM Armonk NY,
USA) a computer language designed for market
research data analysis. Using Quantum, data
were checked, validated and tabulated.
Verbatim responses were reviewed and coded
using Ascribe (Version 8.4, Language Logic,
Cincinnati OH, USA), a comment
management platform. Coded verbatim
responses were imported into Quantum and
integrated into the tabulations. A Quanvert
respondent level data file was exported from
Quantum and imported into IBM SPSS Data
Collection Survey Reporter for further subgroup
analysis. Statistical significance testing between
analytic groups in all cases was performed at the
90% confidence level (Quantum, Version 5.8.1,
IBM Armonk NY, USA).
Study results were weight adjusted to match
an estimate of the U.S. diagnosed adult diabetes
patient population. Data were weighted by age,
gender, race, ethnicity, region, education level,
income, and home internet access.
Demographic weights were derived from the
2012 National Center for Health Statistics
National Health Interview Survey. Weights for
income and education level were derived from
2012 Behavioral Risk Factor Surveillance System
(BRFSS). The home internet access weight was
derived from KnowledgePanel. Results were
projected to a U.S. population of 23,152,000
diagnosed diabetes patients. This population
estimate involved extrapolation of CDC’s
(BRFSS) diagnosed diabetes population
estimates from 1997 to 2012.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
The 2013 US Roper Diabetes Patient Study was
conducted June 18–August 21, 2013, among
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2,307 diagnosed adult (aged 18? years) US
diabetes patients. 768 interviews were
completed by telephone and 1,539 were
completed via the internet. The groups
evaluated in this analysis are based on the self-
reported health insurance source patients
typically used to cover their diabetes
medications and supplies. Within this analysis,
1714 patient responders were included: 791
patients with Medicare, 135 with Medicaid,
and 788 with private (employer or union
based) insurance. Of these patients, 3.8% had
type 1 diabetes and 96.2% had type 2 diabetes.
There is widespread demographic,
employment, and educational differences in
the diabetes patient populations, by payer,
studied (Table 1).
Access to Information
According to the study findings, Medicaid and
Medicare patients have very different access to
and use of information sources as compared to
patients with private insurance. Medicaid
patients have the lowest rate of internet
access, either at home or at work, with 58.1%
versus Medicare with 66.3% (Fig. 1). This is in
contrast to privately insured patients who have
near universal internet access (92.2%). As a
result, the most commonly used information
sources for Medicare and Medicaid patients are
printed periodicals and information from
friends and family, whereas privately insured
patients typically get information from the
internet. Medicare and Medicaid patients also
had a much lower rate of cell phone ownership
with 78.9% and 74.3%, respectively (private:
94.2%). Medicare and Medicaid patients also
have much lower ownership of internet ready
portable devices such as smartphones and
tablets (Medicare: 31.5%/23.6%; Medicaid:
34.0%/9.6%; private: 61.2%/49.0%).
There are also differences in whom patients
go to for information related to their diabetes.
Patients across all three groups exhibited
equally low rates of visiting a diabetes
educator in the past 12 months (Medicaid:
28.7%, Medicare: 25.4%, private: 27.3%).
21.4% of Medicaid patients strongly agree that
they frequently ask their pharmacist questions
pertaining to managing their diabetes at twice
the rate of Medicare and privately insured
patients (Medicaid: 21.4%, Medicare: 12.8%,
private: 11.1%). Medicaid patients also more
frequently report receiving advice about their
diabetes from a social worker (11.5% versus
Medicare: 4.5%, private: 1.4%). Medicaid and
Medicare patients indicate that they would
prefer their doctor or nurse to manage their
diabetes for them more frequently than
privately insured patients (Medicaid: 23.1%,
Medicare: 22.3%, private: 10.9%). Privately
insured patients listed the internet as their
most frequent source of information related to
their diabetes at twice the rate of the other two
insured groups (Private: 40.8%, Medicare:
20.6%, Medicaid: 24.3%) (Supplemental
Table 1).
Lifestyle and Treatment Data
When asked to describe the status of their
‘‘Overall Health’’, Medicaid patients
resoundingly believed themselves to be
unhealthy, with 58.8% selecting ‘‘Fair’’ or
‘‘Poor’’, and only 12.8% selecting ‘‘Excellent’’
or ‘‘Very Good’’. This is drastically different
from Medicare and private insurance patients,
who only have 37.1% and 21.3% claiming
‘‘Fair’’ or ‘‘Poor’’, respectively, and 26.9% and
27.2% claiming ‘‘Excellent’’ or ‘‘Very Good’’,
respectively. (Figure 2a)
As a result of poor general health, 48.0% of
Medicaid patients claim to be out of work
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because of disability (Medicare: 23.4%, private:
4.7%), with 42.5% claiming to be disabled
specifically because of their diabetes (Medicare:
23.7%; private: 3.5%). Similarly, 19.1% of
Medicaid patients reported having ‘‘Poorly
Controlled/Not at all controlled’’ diabetes,
compared to 7.1% and 6.8% of Medicare and
private insurance patients. Close to 10.0% of
Table 1 Demographic and socioeconomic breakdown of diabetes patients in study based on insurance type
Demographics of diabetes patients Medicaid n5 135 Medicare n5 791 Private n5 788
Gender (%)
Male 33 44.3 55.9
Female 67 55.7 44.1
Age (Mean, Years) 52.7 67.4 54.8
Age at Diagnosis (Mean, Years) 41.6 54.7 43.8
Marital Status (%)
Single/Never Married 31.8 12.7 9.7
Married 27.9 42.5 74.2
Separated 5.3 2.5 1.3
Divorced 27.5 19.1 10.3
Widowed 7.5 23.1 4.5
Income (Mean, $USD) 17,260 32,342 64,909
Education Level
Graduated High School or less 72.5 56.9 28.6
Some College or more 27.5 41.6 71.4
Graduated College 9.2 21.4 42.7
$USD-United states dollar
Fig. 1 Reported consumer technology ownership by insurance coverage
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Medicaid patients claim to have ‘‘Severe’’
diabetes, twice that of Medicare and 8 times
that of private insurance (Medicare: 4.0%,
private: 1.1%) (Table 2). This belief is
corroborated by standard HbA1c testing.
When asked to report their most recent HbA1c
test result, among those patients who had test
results available, there is a similarly
disproportionate number of Medicaid patients
who have unhealthy HbA1c levels, with 61.5%
reporting a score higher than or equal to 7
(Medicare: 38.4%, private: 48.9%) (Fig. 2b).
The burden of disease and associated
comorbidities were significantly higher within
Medicare and Medicaid than privately insured
patients, reporting more than 7 other health
problems in addition to diabetes on average
(private:\5). Most notably, 48.3% of Medicaid
patients report having depression (Medicare:
28.8%, private: 23.3%), 20.0% report a history
of stroke (Medicare: 12.4%, private: 2.9%) and
55.0% report pain in hands/feet (Medicare:
39.3%, private: 27.6%). Medicare patients have
the highest reported rate of congestive heart
failure with 15.4% reporting a history
(Medicaid: 7.4%, private: 2.5%).
Lifestyle risk factors can exacerbate diabetes
and associated complications [23–25]. Medicaid
patients have higher rates of lifestyle risk factors
for diabetes than found in other populations.
For example, the level of obesity amongst
Medicaid patients is drastically higher than
Fig. 2 a Rating of overall general health by people with diabetes. b Results of most recent glycated hemoglobin test
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that of the other two groups, with an average
BMI of 36.3, qualifying the average patient of
this population as ‘‘morbidly obese’’ (Medicare:
32.3; private: 33.2). Over half (52.8%) of
Medicaid patients are defined as ‘‘morbidly
obese’’ (Medicare: 31.5%; private: 34.8%).
Similarly, 13.9% of Medicaid patients have
been recommended to have a surgical weight
loss procedure by their HCP (Medicare: 5.6%,
private: 7.7%).
Economic Data
Despite significant differences, Medicare,
Medicaid and privately insured patients all
share similar economic concerns when faced
with treating their diabetes. When prompted
with the statement, ‘‘I am worried about the
cost of treating my diabetes now more than
ever’’, patients in all three groups had a
significant number of respondents who
‘‘Agree’’ or ‘‘Strongly Agree’’ (Medicaid: 44.3%;
Medicare: 32.0%; private: 36.1%). As a result,
the patients were prompted with some
statements to understand how they are coping
with these economic issues. When prompted
with the statement, ‘‘I asked my doctor for a
cheaper or generic medicine’’, responses were
very similar across Medicare, Medicaid and
private insurance patients with 36.8, 38.8 and
40.2%, respectively, responding ‘‘Agree’’ or
‘‘Strongly Agree’’ (Table 2).
Some patients showed alarming methods of
saving money, with many stating that they
have ‘‘reduced the number of visits to their
health care provider in the past year’’ (Medicaid:
31.0%; Medicare: 18.2%; private: 25.8%), and
some even saying that they have ‘‘reduced the
amount of insulin they are taking’’ purely for
economic reasons (Medicaid: 14.1%; Medicare:
10.5%; private: 16.2%) (Table 2).
Despite all of these concerns, however,
patients responded resoundingly that they
were getting coverage for their diabetes
medication from their insurance providers,
especially in the Medicaid group. Even though
14.1% of Medicaid patients claim that they
have cut back on their insulin use for financial
reasons, 60.3% of Medicaid patients paid no
money for their insulin (either covered
Table 2 Patient responses to prompted opinions about the state of their diabetes
(%) Medicaid Medicare Private
(a) Out of work because of disability 48.0 23.4 4.7
(b) Disabled because of diabetes 42.5 23.7 3.5
(c) Diabetes is poorly controlled/not at all controlled 19.1 7.1 6.8
(d) Have severe diabetes 9.3 4.0 1.1
(e) I am worried about the cost of my treatment now more than ever 44.3 32.0 36.1
(f) I asked my doctor for a cheaper or generic medication 38.8 36.8 40.2
(g) I have reduced the number of visits to my HCP for economic reasons 31.0 18.2 25.8
(h) I have reduced the amount of insulin I use purely for economic reasons 14.1 10.5 16.2
(a) Percentage of patients who claim to be out of work because of disability. (b) Percentage of patients who claim to be
disabled because of diabetes. (c) Percentage of patients who rate their diabetes as poorly/not at all controlled. (d) Percentage
of patients who rate their diabetes as severe. (e)–(h) Percentage of patients who agree with the prompted statements
HCP Health care provider
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completely by insurance, or received it free),
with the remaining 39.7% paying only a
nominal copay. This is remarkably different
from the other two groups, with the majority of
both Medicare and private insurance patients
paying a copayment (Medicare: 67.3%, private:
81.0%) and a small population responsible for
100% of the cost of their insulin (Medicare:
2.2%; private: 3.0%) (Fig. 3). Similarly for
payment of diabetes pills, more than 38.8% of
Medicaid patients claim to have asked their
HCP for less expensive options, however, 54.8%
did not pay at all for their diabetes pills, and
39.4% had to pay only a copayment. As with
insulin, the majority of Medicare and privately
insured patients were required to pay a
copayment for their diabetes pills (Medicare:
65.1%; private: 83.5%).
DISCUSSION
Across people with diabetes studied, factors
driving non-adherence were differentially
represented within each insured population,
with greatest burdens most frequently within
the Medicaid group. Independent of insurance
type, however, all patients cited economic
concerns as a key driver of their adherence
and treatment choices. Concerns about out-of-
pocket costs associated with care were present
across groups, even though most have coverage
for their diabetes medicines and testing services.
This is due to the fact that patients in our study
were treating 2–3 comorbidities outside of their
diabetes with prescription medication.
Alleviating or addressing this concern, across
groups, should be considered a priority as
patients report the significant impact on
treatment adherence and other positive health
behaviors such as taking medicine or visiting
their provider [9].
While people with diabetes across payer
groups’ document concerns related to the cost
of their disease and its management, the payers
themselves are struggling to ensure their
patients are better managed, adhere to
treatment protocols and engage in ongoing
education about their illness to support
positive health behaviors. Despite providing
coverage for DSME, we found that all three
patient groups exhibited low utilization rates.
One approach, by payers, has been to leverage
digital health monitoring tools to supplement
engagement and disease management of people
Fig. 3 Patient responsibility for payment of Insulin based on insurance type
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with diabetes. These tools are becoming more
available as the marketplace evolves and
smartphone technologies enable wide
deployment of application-based tools [17, 19,
20]. However, these and other technology based
solutions may not be adopted by patients most
in need; in our study those most prevalent in
the Medicaid population.
Medicaid Covered Diabetes Patients
The Medicaid group report higher rates of
disability, depression, and comorbidities than
the other two groups. Additionally, they report
having economic challenges, low use of
internet-based education systems, and
widespread feelings of hopelessness related to
improving their disease experience. These
factors drive non-adherence to treatment
regimens and result in poorer outcomes.
Disease management and patient engagement
strategies targeting these patients, those most in
need and perhaps the most complex, need to
take these characteristics into account as
solutions are developed. If those patients most
in need have low smartphone ownership and
internet use for health information, then many
digital health and wellness activities targeting
people with diabetes may not be reaching their
target populations. Additionally, with many
patients experiencing comorbidities with their
diabetes, solutions will need to provide support
for the whole patient experience rather than
just the component associated with diabetes
management.
Medicare Covered Diabetes Patients
The Medicare group is generally older, finds
change more difficult, uses the internet for
information sporadically, and has higher
comorbidities than privately insured patients.
Disease management and patient engagement
strategies for this population need to leverage
innovation while also communicating with
patients through media they are comfortable
with and most frequently utilize. Within
Medicare there is likely a greater technological
disparity between those baby boomers who are
newer to the program, internet savvy, and are
actively engaged in managing their health
versus others, who may be older or less
digitally connected. The latter group may
require interventions that are more personal,
less technology driven, and are integrated with
support for other health conditions. In fact, the
Medicare patients in our study that have access
to internet, smartphones and tablets do not
report using these tools for diabetes care and
management. In this regard they are no
different than the Medicaid population, and
education and management programs must
take this into account.
Adherence remains a major challenge among
elderly people with diabetes, especially those
with multiple comorbidities [9, 26]. As such,
realities of Medicare patient’s lives must be
better understood when designing
interventions, especially those factors that
drive poor adherence such as frequently
changing medication regimens, forgetfulness,
negative side effects, inability to access a
pharmacy, economic concerns and lack of
support or unstable living conditions [9].
Privately Insured Diabetes Patients
The privately insured group tends to have less
severe disease, fewer comorbidities, are
younger, tend to be working, and use the
internet frequently to access healthcare
information. As such, interventions targeting
this group can leverage many technology
enabled solutions, such as digital health
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monitors and smart phone applications. Active
patient engagement models can take advantage
of the perspectives documented in this study
related to patients feeling more empowered to
change their own disease course, generally
being more hopeful and compliant.
Additionally, being younger, employed, and
less likely to have comorbidities allow targeted
initiatives to focus on core concerns related to
the disease and life experience of the patients—
leveraging internet-based education models and
employer support systems. While privately
insured patients are likely to have more
resources than their Medicaid and Medicare
counterparts, they still report feelings of
concern related to affording their diabetes
medication and treatments.
This data should be interpreted with the
following limitations in mind. This study
reviews patient reported data, without
examination of medical record or claims data.
As a result, the accuracy of the data is limited by
the patient’s memory and willingness to
provide information. Additionally, this study
was only performed in English and Spanish, and
therefore only includes the views of patients
proficient in one of those two languages.
CONCLUSION
While insurance status is a key determinant of
diabetes outcomes, it is clear that not all insured
people with diabetes are the same. The different
characteristics, behaviors and beliefs
demonstrated when comparing Medicaid,
Medicare and privately insured patients in our
study highlight the need for targeted
interventions to improve diabetes care and
outcomes. These differences can inform how
clinicians, policy makers and the payers
themselves attempt to better manage diabetes
patients and provide individualized solutions that
reflect patients’ experience and preferences.
Additionally, as millions of otherwise uninsured
or underinsured patients enter the Medicaid
population as a result of the ACA, population
characteristics may shift. This is also true as
millions of baby boomers become Medicare
beneficiaries. Understanding the impact of these
shifting population dynamics within each payer
population segment requires ongoing assessment
of patient’s evolving perspectives, experiences and
technology use. With this level of engagement,
new generations of diabetes management
programs are likely to be more effective.
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